Botox vs. Dysport vs. Xeomin vs. Daxxify: What Injectors Should Know

Choosing the right neurotoxin for each patient is one of the most important clinical decisions aesthetic injectors make. While all FDA-approved botulinum toxin type A products work through the same mechanism — blocking acetylcholine release at the neuromuscular junction — their molecular structures, dosing, diffusion patterns, and clinical characteristics differ in ways that affect outcomes.

The Four Major Neurotoxins at a Glance

Dosing Conversions: Getting It Right

The most common dosing error new injectors make is treating Dysport units as equivalent to Botox units. They are not interchangeable:

Clinical Decision-Making: Which Product When?

• Precise, targeted treatment (e.g., DAO, mentalis): Xeomin's reduced diffusion makes it ideal when you want minimal spread to adjacent muscles.

• Large treatment areas (e.g., frontalis): Dysport's greater diffusion can provide smoother coverage with fewer injection points.

• Patients wanting extended duration: Daxxify's 6-month average duration makes it attractive for patients who dislike frequent visits, though cost per treatment is higher.

• Botox resistance concerns: Patients who feel Botox "stopped working" may benefit from Xeomin or Daxxify, as the absence of complexing proteins may reduce antibody formation risk.

Reconstitution & Storage

Proper reconstitution technique directly affects clinical results. Key points: Use preservative-free saline unless otherwise indicated; avoid aggressive shaking which can denature the protein; understand how dilution ratios affect your unit calculations; and store reconstituted product according to manufacturer guidelines — typically refrigerated and used within 24 hours for Botox, up to 72 hours for Dysport, and within 24 hours for Xeomin.